SNDX Q4 2025 Earnings — Syndax Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

SNDXSyndax Pharmaceuticals, Inc.

$2B

Q4 2025 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$68M+791.7% YoY

Gross Profit

$70M102.3% margin

Operating Income

-$63M-91.3% margin

Net Income

-$68M-99.3% margin

EPS (Diluted)

$-0.78

QoQ Revenue Growth

+49.3%

Cash Flow

Operating Cash Flow

-$69M

Free Cash Flow

-$70M

Stock-Based Comp.

$11M

Balance Sheet

Total Assets

$530M

Total Liabilities

$465M

Stockholders' Equity

$65M

Cash & Equivalents

$135M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$68M	$8M	+791.7%
Gross Profit	$70M	$8M	+812.1%
Operating Income	-$63M	-$96M	+35.1%
Net Income	-$68M	-$94M	+27.8%

Revenue Segments

Collaboration revenue

$19M100%